Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Inflammation01:38

Inflammation

Overview
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ideal model in atherosclerosis and dyslipidaemia - does it exist?

Expert opinion on drug discovery·2013
Same author

What is the future for drug development in atherosclerosis and dyslipidaemia?

Expert opinion on drug discovery·2013
Same author

The landscape of drug discovery in atherosclerosis and dyslipidaemia revisited: an update of patenting activity.

Expert opinion on therapeutic patents·2012
Same author

Drug development research: diabetes favored over cardiovascular disease?

Current opinion in investigational drugs (London, England : 2000)·2009
Same author

Animal research: too much faith in models clouds judgement.

Nature·2008
Same author

Selective thyromimetics for atherosclerosis and dyslipidaemia: another old target making progress.

Expert opinion on investigational drugs·2008

Related Experiment Video

Updated: Jun 14, 2026

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

Phospholipase A2s: developing drug targets for atherosclerosis.

Keith Suckling1

  • 1GlaxoSmithKline, 291 Knightsfield, Welwyn Garden City, Hertfordshire AL8 7NH, UK. keith@suckling291.freeserve.co.uk

Atherosclerosis
|April 6, 2010
PubMed
Summary

Phospholipase A2 inhibitors show promise for treating atherosclerosis. Clinical trials for darapladib and varespladib highlight distinct targets and potential therapeutic benefits in cardiovascular disease management.

More Related Videos

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

Related Experiment Videos

Last Updated: Jun 14, 2026

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Atherosclerosis is a complex inflammatory disease.
  • Phospholipases, particularly phospholipase A2 (PLA2) enzymes, play a role in atherogenesis.
  • PLA2 enzymes are implicated in lipid metabolism and inflammatory pathways relevant to cardiovascular health.

Purpose of the Study:

  • To review the scientific basis for targeting phospholipase A2 enzymes in atherosclerosis.
  • To discuss the distinct roles of lipoprotein-associated PLA2 (Lp-PLA2) and secreted PLA2s (sPLA2s) in atherogenesis.
  • To evaluate the clinical trial data supporting the development of PLA2 inhibitors.

Main Methods:

  • Review of preclinical and clinical data on PLA2 inhibitors.
  • Analysis of in vitro and in vivo studies on PLA2 function in atherosclerosis.
  • Examination of Phase 2 clinical trial results for darapladib and varespladib.

Main Results:

  • Phase 2 clinical trials for darapladib (Lp-PLA2 inhibitor) and varespladib (sPLA2 inhibitor) have been published.
  • Distinct biological roles and therapeutic potentials exist for targeting Lp-PLA2 versus sPLA2s.
  • Data support the progression of these inhibitors into Phase 3 clinical trials.

Conclusions:

  • Targeting specific phospholipase A2 enzymes represents a promising therapeutic strategy for atherosclerosis.
  • Further clinical investigation is warranted for both Lp-PLA2 and sPLA2 inhibitors.
  • Emerging research also indicates potential for cytosolic PLA2 targets.